Literature DB >> 25935438

Incidence and clinical significance of late right heart failure during continuous-flow left ventricular assist device support.

Koji Takeda1, Hiroo Takayama2, Paolo C Colombo3, Melana Yuzefpolskaya3, Shinichi Fukuhara2, Jiho Han2, Paul Kurlansky2, Donna M Mancini3, Yoshifumi Naka2.   

Abstract

BACKGROUND: Right heart failure (RHF) is an unresolved issue during continuous-flow left ventricular assist device (LVAD) support. Little is known about the incidence and clinical significance of late RHF during LVAD support.
METHODS: Between May 2004 and December 2013, 336 patients underwent continuous-flow LVAD implantation. Of these, 293 patients (87%) discharged with isolated LVAD support were included in this study. Late RHF was defined as HF requiring re-admission and medical or surgical intervention after initial surgery.
RESULTS: Late RHF occurred in 33 patients (11%) at a median of 99 days after discharge (range 19 to 1,357 days). Freedom from late RHF rates were 87%, 84% and 79% at 1, 2 and 3 years, respectively. RHF recurred in 15 patients. Three patients required right ventricular assist device insertion. Univariable Cox proportional hazards regression model showed diabetes mellitus (HR 2.05, 95% CI 1.03 to 4.06, p = 0.04), body mass index >29 (HR 2.47, 95% CI 1.24 to 4.94, p = 0.01) and blood urea nitrogen level >41 mg/dl (HR 2.19; 95% CI 1.10 to 4.36; p = 0.025) as significant predictors for late RHF. Estimated on-device survival rates at 2 years were 73% in the RHF group and 82% in the non-RHF group (p = 0.20). However, overall survival at 2 years was significantly worse in patients who developed late RHF (60% vs 85%, p = 0.016). This reduction was mostly attributed to worse overall outcomes in the bridge-to-transplant (BTT) population.
CONCLUSIONS: Late RHF is common after continuous-flow LVAD implantation, but does not affect survival during LVAD support. However, it is associated with worse overall outcomes in the BTT population. Published by Elsevier Inc.

Entities:  

Keywords:  Bridge to transplant; Destination therapy; continuous flow; right heart failure; transplantation; ventricular assist device

Mesh:

Year:  2015        PMID: 25935438     DOI: 10.1016/j.healun.2015.03.011

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  24 in total

1.  Longitudinal Trajectories of Hemodynamics Following Left Ventricular Assist Device Implantation.

Authors:  Takeo Fujino; Aline Sayer; Daisuke Nitta; Teruhiko Imamura; Nikhil Narang; Ann Nguyen; Daniel Rodgers; Jayant Raikhelkar; Bryan Smith; Gene Kim; Colleen LaBuhn; Valluvan Jeevanandam; Daniel Burkhoff; Gabriel Sayer; Nir Uriel
Journal:  J Card Fail       Date:  2020-02-03       Impact factor: 5.712

2.  Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure.

Authors:  Amresh Raina; Talha Meeran
Journal:  Curr Heart Fail Rep       Date:  2018-04

Review 3.  Left Ventricular Assist Device as Destination Therapy: a State of the Science and Art of Long-Term Mechanical Circulatory Support.

Authors:  Thomas C Hanff; Edo Y Birati
Journal:  Curr Heart Fail Rep       Date:  2019-10

4.  Effect of Concomitant Tricuspid Valve Surgery With Left Ventricular Assist Device Implantation.

Authors:  Takeo Fujino; Teruhiko Imamura; Daisuke Nitta; Gene Kim; Bryan Smith; Sara Kalantari; Ann Nguyen; Ben Chung; Nikhil Narang; Luise Holzhauser; Colleen Juricek; Daniel Rodgers; Tae Song; Takeyoshi Ota; Valluvan Jeevanandam; Daniel Burkhoff; Gabriel Sayer; Nir Uriel
Journal:  Ann Thorac Surg       Date:  2020-02-06       Impact factor: 4.330

Review 5.  Clinical implications of hemodynamic assessment during left ventricular assist device therapy.

Authors:  Teruhiko Imamura; Ben Chung; Ann Nguyen; Gabriel Sayer; Nir Uriel
Journal:  J Cardiol       Date:  2017-12-26       Impact factor: 3.159

6.  Right Heart Failure Following Left Ventricular Device Implantation: Natural History, Risk Factors, and Outcomes: An Analysis of the STS INTERMACS Database.

Authors:  Chris J Kapelios; Lars H Lund; Omar Wever-Pinzon; Craig H Selzman; Susan L Myers; Ryan S Cantor; Josef Stehlik; Themistocles Chamogeorgakis; Stephen H McKellar; Antigone Koliopoulou; Rami Alharethi; Abdallah G Kfoury; Michael Bonios; Stamatis Adamopoulos; Edward M Gilbert; James C Fang; James K Kirklin; Stavros G Drakos
Journal:  Circ Heart Fail       Date:  2022-06-06       Impact factor: 10.447

7.  Durability and Efficacy of Tricuspid Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation.

Authors:  Yaron D Barac; Alina Nicoara; Muath Bishawi; Jacob N Schroder; Mani A Daneshmand; Nazish K Hashmi; Eric Velazquez; Joseph G Rogers; Chetan B Patel; Carmelo A Milano
Journal:  JACC Heart Fail       Date:  2019-12-11       Impact factor: 12.035

Review 8.  A right ventricular state of mind in the progression of heart failure with reduced ejection fraction: implications for left ventricular assist device therapy.

Authors:  Ersilia M DeFilippis; Marco Guazzi; Paolo C Colombo; Melana Yuzefpolskaya
Journal:  Heart Fail Rev       Date:  2021-11       Impact factor: 4.214

9.  Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices.

Authors:  Takeo Fujino; Teruhiko Imamura; Ann Nguyen; Ben Chung; Jayant Raikhelkar; Daniel Rodgers; Daisuke Nitta; Bryan Smith; Nitasha Sarswat; Sara Kalantari; Nikhil Narang; Colleen LaBuhn; Valluvan Jeevanandam; Gene Kim; Gabriel Sayer; Nir Uriel
Journal:  ASAIO J       Date:  2020-03       Impact factor: 3.826

10.  Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices.

Authors:  Alaide Chieffo; Dariusz Dudek; Christian Hassager; Alain Combes; Mario Gramegna; Sigrun Halvorsen; Kurt Huber; Vijay Kunadian; Jiri Maly; Jacob Eifer Møller; Federico Pappalardo; Giuseppe Tarantini; Guido Tavazzi; Holger Thiele; Christophe Vandenbriele; Nicolas van Mieghem; Pascal Vranckx; Nikos Werner; Susanna Price
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.